Sofosbuvir and Daclatasvir Combination Therapy in a Liver Transplant Recipient With Severe Recurrent Cholestatic Hepatitis C
Open Access
- 1 June 2013
- journal article
- case report
- Published by Elsevier in American Journal of Transplantation
- Vol. 13 (6), 1601-1605
- https://doi.org/10.1111/ajt.12209
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis CNew England Journal of Medicine, 2013
- Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trialThe Lancet Infectious Diseases, 2012
- Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteersHepatology, 2012
- Risk for Immune-Mediated Graft Dysfunction in Liver Transplant Recipients With Recurrent HCV Infection Treated With Pegylated InterferonGastroenterology, 2012
- Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1New England Journal of Medicine, 2012
- Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimusHepatology, 2011
- Systematic review: anti-viral therapy of recurrent hepatitis C after liver transplantationAlimentary Pharmacology & Therapeutics, 2010
- Hepatitis C Virus and Liver TransplantationClinics in Liver Disease, 2006
- The association between hepatitis C infection and survival after orthotopic liver transplantationGastroenterology, 2002
- A longitudinal analysis of hepatitis C virus replication following liver transplantationGastroenterology, 1996